The current pandemic is due to the spread of SARS-CoV-2, a novel coronavirus that causes a severe respiratory infection known as COVID-19. Recent reports have noted the presence of viral RNA in stool samples, offering unique measurement challenges and opportunities in three areas:
Biosurveillance of Wastewater: Local public health labs can monitor sewage treatment facilities to measure the rise and fall of COVID-19 in a community; potentially as a tool to help predict future waves of outbreaks.
Feces as a New Target for Diagnostic Testing: Currently there are >140 commercially available COVID-19 diagnostic tests. While initially validated using nasal swabs, these same tests can potentially be re-validated in fecal material.
Fecal Microbiome Transplantation (FMT) Safety: Every year, thousands of patients receive FMTs to treat infections and other health conditions. The FDA has released a safety alert stating donor material must be screened for COVID-19, as feasible.
1:00 pm Scott Jackson, NIST, Opening Remarks
1:05 pm Bharat Ramakrishna, OpenBiome, “Fecal microbiota transplantation: Responding to the COVID-19 pandemic”
1:20 pm Manoj Dadlani, CosmosID, “Overcoming the Validation Challenges of a Diagnostic for SARS-CoV-2 in Stool”
1:35 pm Katerina Papp, Water Quality R&D, Southern Nevada Water Authority, “Wastewater Surveillance of SARS-CoV-2 in Southern Nevada: Challenges for Sample Collection, Processing, and Analysis”
1:50 pm Kyle Bibby, University of Notre Dame, Title TBA
2:05 pm Aparna Keshaviah, Mathematica, “Testing Wastewater for SARS-CoV-2: Aligning Validation and Policy Needs”
2:20 pm Panelist Q&A
2:55 pm Scott Jackson, NIST, Wrap-Up
3:00 pm Conclude Webinar